14 October 2013
Recently receiving media attention, Abcodia is being recognised as an innovator in the discovery and verification of cancer screening.
Collaborating with UCLB to license the use of the “risk of ovarian cancer algorithm” (ROCA); Abcodia are able to monitor and analyse proteins and biomarkers in the blood enabling them to detect cancers long before symptoms develop in the patient.
This early detection of cancer means that patients five year survival rate is increased from 20% to 85%. It is a great leap forward in the area of cancer research and screening, with the potential to make life changing differences.
Read the full article from the Telegraph here.
Abcodia is a specialist company engaged in the developing biomarkers for the early detection of cancer. The company has developed deep expertise in the methods and technology relevant to the discovery and validation of biomarkers that can be detected well before the symptomatic presentation of cancer. Through an exclusive commercial license to the UKCTOCS biobank, the company is able to use samples from this population cohort to develop a pipeline of diagnostic products for the early detection of a range of cancers.
For further information, please see: www.abcodia.com
UCLB is a leading technology transfer company that supports and commercialises research and innovations arising from UCL, one of the UK’s top research-led universities.
UCLB has a successful track record and a strong reputation for identifying and protecting promising new technologies and innovations from UCL academics. It invests directly in development projects to maximise the potential of the research and manages the commercialisation process of technologies from the laboratory to market.
UCLB supports UCL’s Grand Challenges of increasing UCL’s positive impact on and contribution to Global Health, Sustainable Cities, Intercultural Interaction and Human Wellbeing.
For further information, please visit: www.uclb.com